Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Sharks Do Get Cancer: Few Surprises in Cartilage Research

Sharks Do Get Cancer: Few Surprises in Cartilage Research NE W S NEWS Sharks Do G et Cancer: Few Surprises in Cartilage Research As is the case for many alternative Benefi n, was manufactured by Lane professor at the University of Texas remedies, dozens of shark cartilage Labs, a company run by his son. In M. D. Anderson Cancer Center in products for a variety of medical condi- 1999, the U.S. Food and Drug Adminis- Houston and principal investigator for tions are already on the market despite tration pursued an injunction against the the NCI study. “ The company has never a lack of strong clinical evidence to company for illegally promoting the made any money off of Neovastat, ” said support their effectiveness. product as a cancer treatment. Lu. “ It is being treated as if it were an Although some laboratory studies And when Benefi n was tested in a experimental drug. ” have shown that shark cartilage may placebo-controlled trial, no benefi t was Federal law allows natural products have antiangiogenic properties, it re-found. “ It such as Neovastat and Benefi n to be mar- mains unclear whether future research wasn’t well keted as dietary supplements, although will ultimately clarify troubling ques- tolerated, there the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JNCI: Journal of the National Cancer Institute Oxford University Press

Sharks Do Get Cancer: Few Surprises in Cartilage Research

Download PDF
2 pages

Loading next page...
 
/lp/oxford-university-press/sharks-do-get-cancer-few-surprises-in-cartilage-research-MXTZxam9Zz

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Oxford University Press
Copyright
© The Author 2005. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org.
ISSN
0027-8874
eISSN
1460-2105
DOI
10.1093/jnci/dji392
pmid
16264172
Publisher site
See Article on Publisher Site

Abstract

NE W S NEWS Sharks Do G et Cancer: Few Surprises in Cartilage Research As is the case for many alternative Benefi n, was manufactured by Lane professor at the University of Texas remedies, dozens of shark cartilage Labs, a company run by his son. In M. D. Anderson Cancer Center in products for a variety of medical condi- 1999, the U.S. Food and Drug Adminis- Houston and principal investigator for tions are already on the market despite tration pursued an injunction against the the NCI study. “ The company has never a lack of strong clinical evidence to company for illegally promoting the made any money off of Neovastat, ” said support their effectiveness. product as a cancer treatment. Lu. “ It is being treated as if it were an Although some laboratory studies And when Benefi n was tested in a experimental drug. ” have shown that shark cartilage may placebo-controlled trial, no benefi t was Federal law allows natural products have antiangiogenic properties, it re-found. “ It such as Neovastat and Benefi n to be mar- mains unclear whether future research wasn’t well keted as dietary supplements, although will ultimately clarify troubling ques- tolerated, there the

Journal

JNCI: Journal of the National Cancer Institute – Oxford University Press

Published: Nov 2, 2005

There are no references for this article.